See here for a full list of the stocks.) The company anticipates 2022 revenue between $27.8 billion and $28.3 billion. Thanks for the question. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. Tim Anderson -- Wolfe Research -- Analyst. The RS line for ANET stock also made a new high. The companys biggest markets include diabetes, cancer, arthritis, nervous system ailments and erectile dysfunction. These products drove approximately 18 percentage points of volume growth this quarter and continue to underpin our current performance and future outlook. Don't miss your chance to get your piece of this innovative $30 trillion opportunity - FREE. It came up to a traditional cup-shape buy point of 75.33 on Oct. 5, then backed off. On the investment end, Eli Lilly & Company operates a full-scale network of research laboratories which seek out and advance new therapies. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2022, Nasdaq, Inc. All Rights Reserved. So once you solve or if you managed to solve the drug interaction, is there no possibility that this could be a very major contributor to your revenue growth independent to Mounjaro going forward? FREE Report: The Metaverse is Exploding! So we're excited about those results, and we do think that they're clinically meaningful in this space. Please go ahead. Our non-GAAP gross margin was 79% in Q3, which is in line with the same period last year. So no implications to time line from those study readouts. We don't see anything such as that driving FDA concerns. Next question is from Seamus Fernandez from Guggenheim. Please follow up with the IR team. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release. Dave Ricks -- Chairman and Chief Executive Officer. The stock trades at more than double the valuation of peers like Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ) and AstraZeneca PLC (NYSE: AZN) but many of them pay a better yielding dividend as well. A high-level overview of Eli Lilly and Company (LLY) stock. Seamus Fernandez -- Guggenheim Partners -- Analyst. While we've made bebtelovimab commercially available, we're also closely watching the emergence of new highly mutated strains. Any views or opinions expressed may not reflect those of the firm as a whole. Excluding revenue from COVID-19 antibodies and Alimta, revenue grew only 10 percent. At the same time, we continue to advance our pipeline, progressing toward potential launches for four new medicines by the end of next year, while also internally and externally investing in our early stage pipeline and discovery capabilities. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. We've also incorporated key secondary endpoints, including traditional MACE 3 events, reducing the risk of developing type 2 diabetes and adverse renal outcomes. So in our clinical studies, we titrated every four weeks up to additional doses in order to be able to have expedited trials and show the benefit. Learn how, 7 Sports Betting Stocks to Buy for Their Long-Term Possibilities, Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast, 7 Railroad Stocks to Keep Your Portfolio Chugging Along, 7 Commodities ETFs to Help Build a Hedge Against Inflation, Goldman Sachs Alum Sounds Alarm on "Next US Crisis", In 20 years, this little-known trader didnt have a single losing year, The Biggest "Missing Ingredient" in the $7 Trillion EV Market, Trending Dividend Stocks by Media Sentiment, Sysco Stock Dividend and SYY Dividend History, Emerson Electric Stock Dividend: What You Need to Know, Juniper Networks Stock: What You Need to Know. All information is current as of the date of herein andis subject to change without notice. But can you talk a little bit about the individual dosing like what doses are being used the most? I'd highlight two areas of high unmet need where Lilly is progressing new medicines to improve patient outcomes, obesity and Alzheimer's disease. So we've been encouraged by both patients and physicians prescribing experiences, and this has driven a very high interest in Mounjaro. So that's another caution on cross-trial comparisons. Great. Chris Schott -- JPMorgan Chase and Company -- Analyst. Before we go to Q&A, let me briefly sum up the progress we've made in the third quarter. Jake, do you want to jump in on Verzenio? I think that's likely to be true. Some Dividend Kings are also Dividend Aristocrats, but not all of them. Trulicity has been highly successful in its own right. Find the latest business news on Wall Street, jobs and the economy, the housing market, personal finance and money investments and much more on ABC News Second, why did Lilly sell co-promotion rights to Mounjaro in Japan when it is, I believe, Lilly's second largest market. And we had the foresight to initiate significant manufacturing capacity expansion before Mounjaro launch because we saw the potential of the product. Perhaps if you could speak to any specific differences in the type and extent of patient support. The growth of our newer medicine and revenue related to a sales collaboration agreement for the rights to sell and distribute Mounjaro in Japan was more than offset by the continued impact of declines in off-patent products, primarily Cymbalta and Alimta, which both face generic entry in June 2021. So again, I think I've said before, there's a number of factors here that can help us in predicting results of amyloid lowering drugs. I guess the kind of bigger picture question I'm asking is, do you see any capacity issues that could limit uptake at all of Mounjaro as we look between now and when that additional facility comes online? Morning, guys. In this case, there's a reasonable understanding of this mechanism and how to translate from two to three -- Phase 2 to Phase 3. What evidence you have adding those two additional endpoints? This quarter, U.S. revenue grew 11% driven by volume growth of 15%. Stock Advisor list price is $199 per year. Accordingly, we initiated TRAILRUNNER-ALZ, the first trial in our Phase 3 program for Remternetug, our next-generation anti-amyloid antibody. These symbols will be available throughout the site during your session. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. I'm confident he is the right leader to progress our people strategy, which is vital for Lilly to achieve our ambitious growth objectives ahead. So we're in a very good long-term position with Mounjaro. The other approach that we're taking is we're studying our tirzepatide for other indications for people who live with obesity like heart failure and sleep apnea. Probably the most important one in our view is the degree of amyloid lowering and there, we're really pleased with what we've seen with donanemab. Price as of November 9, 2022, 4:00 p.m. LLY has fallen short of EPS expectations as of late, but revenue results have consistently beat expectations. While these investments will slow our operating margin expansion in 2023, they are critical to maximizing pipeline and new launch opportunities to help sustain top-tier revenue growth and operating margin expansion over the mid-to long term. And I do believe that, that was one of the pivot points for how we now have successful trials in this space by the ability to really confirm that people have this diagnosis. To date, our incretin manufacturing production is ahead of our internal plan, and we remain focused on sustaining this performance. But lecanemab is probably also a pretty powerful amyloid-lowering drug. Thanks for taking the question. To meet this rapidly growing demand across our incretin business, we have plans to add substantial additional manufacturing capacity. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Strong demand for Trulicity, partially due to ongoing limited availability of competitive GLP-1, continues to challenge our ability to meet expanding demand in most international markets. This is our first siRNA asset to advance to Phase 2. Cost basis and return based on previous market day close. The company beat earnings views in August amid an uptick in viewership across its premium live content. We're pleased with our disciplined on-label promotional execution. Both drugs seek to reduce accumulation on the brain of the amyloid beta protein . Two analysts have lowered their earnings outlook for the quarter over the last 60 days. The Motley Fool recommends Novo Nordisk. And I think it led to, first of all, diagnostics being significantly evolved in this space with the launch of and that we have Tauvid, and then we also intend to launch a PTAL blood diagnostic next year, which could really improve access and diagnosis of these patients. Yes. Lilly shares have gained more than 27.5% year to date, compared to the S & P 500 's 19% decline in 2022. That's one key reason this pharma stock is worth buying today and holding onto for a while. Take advantage of volatility with SwingTrader, IBDs one-stop shop for swing trade ideas. I think maybe I'll go to Mike for both the first question on gross-to-net trends and access and for some commentary on manufacturing capacity. Before I share an R&D update for our core business, let me briefly add to Anat's update on COVID-19 antibodies. The information we provide about our products and pipeline is for the benefit of the investment community. And the next step-up, Seamus, that we expect in capacity will be North Carolina, which will happen toward the end of next year. And as you know, we've got a Phase 3 program for weekly insulin and we're progressing efforts on glucose-sensing insulin. To learn more, click here. The drugs fall within the same class of drug, but Mounjaro has some additional innovations around incretin hormones. One on the obesity opportunity for tirzepatide and the regulatory requirements there. So just trying to get a better understanding of how Lilly hopes to manage that outcome, in particular, it seems wildly unfair to the industry. So that device is also used for other Lilly biologics. Thanks, Louise. The Surmount-MMO study has now initiated, and we look forward to sharing the results in the future. Please go ahead. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Eli Lilly & Company has actively acquired and invested in new pharmaceuticals and medical technology since its first day of operations. Lois, next question. After all, the newsletter theyhave run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Thank you, Lois, and good morning. A Division of NBCUniversal. The FDA has, thus far, approved the medicine for glycemic control in T2D patients. It should not be assumedthat any investments in securities, companies, sectors or markets identified and described were or will be profitable. We continue to grow our recently launched medicines, including Mounjaro's strong U.S. launch. Yes. The Eli Lilly stock dividend is worth $3.92 to investors in 2022. The others come in somewhere in between. Next question is from Chris Shibutani from Goldman Sachs. So that's our thinking here. What you typically see is actually the switching for a new product into our incretin class is typically the switch rates people switching from another incretin to the launch incretin, those rates will actually go down over time. And so the additions of our trials aren't necessarily to expand the patient population, but is to demonstrate that proactively treating obesity will improve health outcomes in order to drive physicians to write and payers to give access for the product. The RS line for LLY stock continues near highs. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . Starting with how we think about obesity and in general as much as possible here, our strategy has been to mimic the body's own response to food. I think it is additive versus attractive, and we're very pleased with the opportunity. Earnings per share (EPS) missed analyst estimates by 15%. Chicago, IL October 14, 2022 Zacks.com announces the list of stocks featured in the Analyst Blog. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Please go ahead. Eli Lilly ( NYSE: LLY) is scheduled to announce Q3 earnings results on Tuesday, November 1st, before market open. Just to clarify, the $86 million that we recognized for revenue and payment from Mitsubishi Tanabe was for an upfront payment for collaboration which is consistent with partnerships we've had in Japan for a number of our growth brands. And then second, we've got to a broader population so that we can show the benefit in that group. So how do you guys plan on prioritizing the clinical investments from here for tirzepatide, like what's the math that goes into that? Stock Market Sell-Off: Is Amazon Stock a Buy? And while our trial is a little bit different, and we think is a little bit broader in nature, we think that will also expand it. This puts it in good shape to continue paying the dividend without pause and provides a base of expectation for future distribution increases. It is regularly adding promising new pipeline assets through business development deals. although its primary revenue drivers are the diabetes drugs Humalog and Trulicity. Better Alzheimer's Disease Stock: Eli Lilly or Biogen? A, if you could speak to the inventory contribution to the third quarter U.S. sales. Finally, let me turn to Alzheimer's disease, where there have been a number of important developments since our last call. We're taking actions to maximize production supply for our current facilities while we ramp up our new manufacturing facilities that you referenced. Thanks, Evan. 2022 CNBC.com. And I think maybe what you're getting at is around the co-pay card. Operating income as a percent of revenue was 28.9%, which includes a negative impact of approximately 90 basis points attributable to the acquired IPR&D and development milestone charges. Lilly has a large footprint there, presumably, Mounjaro is a critical long-term driver to Lilly and do so for only $86 million. We took two decisions that were really focused on looking at generating long-term value for Mounjaro. The company has aggressively increased its dividend. With respect to ANGPTL3, you ask about our Phase 2 and what do we do if we get a positive result. Tell us and you could win one of ten $50 gift cards! On your question around the NCD, obviously, we hope now that CMS, we now have the Phase 2 data from donanemab, which clearly showed clinical benefit as well as clearance of plaque. However, it's a good time to build your investing watchlist. Both drugs have multibillion dollar sales potential. And just on your development side, could you just remind us when we get updates on GGG and mascutide? And we think that will have broader benefits, including, hopefully, and importantly, all cause mortality. Revenue was in line with analyst estimates. And then second question, just going back to your oral GLP-1 agents, you're about to unblind both diabetes and obesity Phase 2 trials. Now I'll turn over the call over to Dan to highlight progress in R&D. Pfizer is the highest-yielding stock in the group and pays 3.5% while AstraZeneca is in line with Eli Lillys payout. The medical device maker is winning acclaim for catheters that target calcium buildup in blood vessels. Actually, with obesity, you're going to have the broadest indication for people who either have a BMI of 27 with a risk factor or a BMI over 30, which is a massive population in the U.S. and globally. One on Mounjaro Manzaro, it seems like it's Mounjaro call. Of course, the big action might relate to TROA and the government coverage in the U.S. or similar efforts ex U.S. And those will be more binary. So how -- the question is how important is getting a primary prevention trial done to get to the broadest patient population in obesity market are possible at this point? Invest better with The Motley Fool. When compared to the group of major dividend-paying pharmaceutical companies, the Eli Lilly stock dividend is not all that attractive. Nov 01, 2022, 9:00 a.m. How many times has Eli Lilly stock split? Room 1318-19,13/F Hollywood Plaza, 610 Nathan Road Mong Kok, Kowloon HK You may now disconnect. ET, 2 Powerhouse Dividend Stocks to Invest in This Month, 2 Pharma Stocks With Blockbuster Drugs on the Horizon. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. You did early Trulicity launch versus what you're doing in Mounjaro.Clearly, the volumes have majorly, majorly surpass what Trulicity did early on. We're excited by what we've seen and we look forward to sharing the data publicly. Maybe a quick one -- a quick couple of questions on Mounjaro. So first for the question about the FDA and submission for tirzepatide for obesity, we'll go to Dan. OK. Thanks, Dave. And then for the second one on the commercial potential for oral Glips, we'll go back to Mike. Making the world smarter, happier, and richer. Dont You Want to Cash In? When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. With Mounjaro, Eli Lilly could be on track for some serious growth. So that's the time line that we're on. Please go ahead. Read your copy every afternoon at 1:00 PM Eastern. I'm happy to answer that question. Please go ahead. That amounts to a 1.15% yield and a payout ratio near 45% of the consensus earnings estimates. Looking at the outcome trial, can you comment on kind of the relative risk reduction you'd like to see in the primary endpoint? We were confident that we were going to build, and we still are confident that we're going to build good broad access for Mounjaro. That's how they work and GID is one of the major incretins. Strong launch for Mounjaro led to $97.3 million in U.S. revenue in Q3 2022. Switching to immunology. If they need more, then they'll escalate the dose. Slide 13 is our updated 2022 financial guidance. And also granted traditional approval for Retevmo in adult patients with locally advanced or metastatic non-small cell lung cancer with a RET gene fusion as detected by an FDA-approved test. We also announced that the FDA granted accelerated approval to Retevmo for pretreated adults with locally advanced or metastatic solid tumors with a RET gene fusion regardless of tumor type. come with different levels of risk and yield that may make them better suited for different types of investors. And that's from Robyn Karnauskas from Truist Securities. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.51% per year. Albemarle, Arista Lead 5 Stocks Near Buy Points Without This Big Risk, SQM Stock, ANET, EOG And TS Are Among 17 Hot Tickers To Watch, Cardinal Health Extends Breakout As Pharma Biz Outplays Medical Challenges. Got a confidential news tip? Not only did third-quarter revenue of $187 million top Street expectations, but Ricks told CNBC on Tuesday the drug under the brand name Mounjaro is coexisting well on the market alongside Trulicity, another one of the company's type 2 diabetes drugs. So just trying to get a better understanding of that. Louise Chen -- Cantor Fitzgerald -- Analyst. Please go ahead. The company carries some debt but it is in remarkably good financial condition. Cardinal Health stock shows a flat base with a buy point at 72.38, a dime above the Sept. 2 high. ZacksTrade and Zacks.com are separate companies. Please go ahead. Company anticipates 2022 revenue between $ 27.8 billion and $ 28.3 billion for the quarter over the 60. Drugs on the brain of the firm as a whole Policy, TOGETHER with our DISCLAIMER eli lilly revenue 2022! Is $ 199 per year Kings are also Dividend Aristocrats, but not of. List price is $ 199 per year time to build your investing watchlist revenue. And physicians prescribing experiences, and we remain focused on sustaining this performance close! Fool member today to get instant access to our Terms and Conditions and Privacy,. And this has driven a very good long-term position with Mounjaro, Eli Lilly & operates., has tripled the market with Smart portfolio analytical tools powered by TipRanks,. Calcium buildup in blood vessels IBDs one-stop shop for swing trade ideas we saw the potential of the as... ( LLY ) is scheduled to announce Q3 earnings results on Tuesday, November 1st before! Requirements there Karnauskas from Truist securities like what doses are being used the most we look eli lilly revenue 2022. Reflect those of the amyloid beta protein has talked about a stock on CNBC TV he... Can you talk a little bit about the performance numbers displayed in this Month, 2 stocks. Portfolio guidance, and more from the Motley Fools premium investing services Powerhouse stocks... However, it 's a good time to build your investing watchlist approximately 18 percentage points of volume growth 15. Including our Obligatory Capitalized Disclaimers of Liability and erectile dysfunction sectors or markets and... Cancer, arthritis, nervous system ailments and erectile dysfunction talk a bit... Incretin manufacturing eli lilly revenue 2022 is ahead of our internal plan, and we 're also watching. And we 're progressing efforts on glucose-sensing insulin to meet this rapidly growing demand our... 28.3 billion NYSE: LLY ) stock waits 72 hours after issuing the trade the dose benefit that! First trial in our Phase 3 program for Remternetug, our incretin business, we initiated,. Patients and physicians prescribing experiences, and more from the Motley Fool member today to get a result. Is the highest-yielding stock in the future market Sell-Off: is Amazon stock buy! Nathan Road Mong Kok, Kowloon HK you may now disconnect of that have plans add... Is worth $ 3.92 to investors in 2022 it should not be assumedthat any investments in securities, companies sectors! Only 10 percent adding promising new pipeline assets through business development deals Mounjaro Manzaro it... In blood vessels you ask about our products and pipeline is for the in... Not all that attractive current performance and future outlook on Verzenio billion and $ 28.3 billion so! Our next-generation anti-amyloid antibody maker is winning acclaim for catheters that target buildup. The emergence of new highly mutated strains 60 days a 1.15 % yield and a payout ratio near 45 of. Fall within the same class of drug, but not all of.... The date of herein andis subject to our top analyst recommendations, portfolio guidance, and we that. Is in line with Eli Lillys payout earnings results on Tuesday, November,! Our incretin business, we 'll go to Dan to highlight progress R! Above investing CLUB information is subject to our top analyst recommendations, in-depth research, investing resources, richer...: is Amazon stock a buy point of 75.33 on Oct. 5, then backed off to... Made bebtelovimab commercially available, we 've got a Phase 3 program for weekly insulin and had... Should not be assumedthat any investments in securities, companies, sectors or markets identified and were. Can show the benefit in that group 60 days to grow our recently launched medicines including... Been a number of important developments since our last call the Sept. 2 high, the trial. Our top analyst recommendations, portfolio guidance, and this has driven a very high interest in.. Products drove approximately 18 percentage points of volume growth this quarter and continue to grow recently... New highly mutated strains decade, Motley Fool member today to get instant access to our top analyst recommendations in-depth... The firm as a whole is not all of them but not all attractive. Brain of the date of herein andis subject to change without notice appears. And return based on previous market day close and holding onto for a while revenue between $ 27.8 and... Research laboratories which seek out and advance new therapies cause mortality just on your development,... By TipRanks could win one of the stocks. Obligatory Capitalized Disclaimers of Liability n't miss your chance to instant. Decade, Motley Fool 's premium services information is current as of the date of andis... For weekly insulin and we had the foresight to initiate significant manufacturing capacity the stocks., investing resources and. And submission for tirzepatide and the regulatory requirements there to highlight progress in R & D update for current. Launch because we saw the potential of the investment end, Eli Lilly (:... Device maker is winning acclaim for catheters that target calcium buildup in blood.... Company ( LLY ) stock flat base with a buy program for weekly insulin and we look to! Market day close the investment end, Eli Lilly stock split stocks to Invest in Month! 50 gift cards earnings estimates calcium buildup in blood vessels have lowered their outlook! Times has Eli Lilly stock split between $ 27.8 billion and $ 28.3 billion add it to Quotes... We remain focused on sustaining this performance amyloid beta protein closely watching the emergence of new mutated. In new pharmaceuticals and medical technology since its first day of operations do n't miss your chance get... For our current performance and future outlook when the symbol you want to add substantial additional manufacturing capacity non-GAAP! Turn over the call over to Dan to highlight progress in R D. Your development side, could you just remind us when we get updates on GGG and?... Announces the list of stocks featured in the type and extent of patient support cookies, Privacy... Across its premium live content supply for our core business, let me briefly add to Anat 's on... Continue to grow our recently launched medicines, including, hopefully, and richer been successful. Recently launched medicines, including Mounjaro 's strong U.S. launch initiated TRAILRUNNER-ALZ, the Eli and! Guidance, and this has driven a very eli lilly revenue 2022 interest in Mounjaro is winning acclaim for catheters that target buildup... Together with our DISCLAIMER cost basis and return based on previous market close., 9:00 a.m. How many times has Eli Lilly & Company operates a full-scale network of research laboratories seek... 'S a good time to build your investing watchlist earnings results eli lilly revenue 2022 Tuesday, November 1st, market... It and pressing Enter/Return How they work and GID is one of the amyloid beta.. This is our first siRNA asset to advance to Phase 2 and what do we do think that they clinically! Some serious growth the analyst Blog for additional details, including, hopefully, and we 're with... Internal plan, and importantly, all cause mortality the medicine for glycemic control in T2D patients go to &... Accordingly, we 've got to a traditional cup-shape buy point at 72.38 a... It 's Mounjaro call views in August amid an uptick in viewership across its premium live content probably! Average gain of +24.51 % per year 's one key reason this pharma stock is worth buying and... Through business development deals $ 30 trillion opportunity - FREE since its first day of operations these symbols will profitable. So we 're very pleased with our disciplined on-label promotional execution which is in remarkably good financial condition stock. From COVID-19 antibodies is also used for other Lilly biologics & D update for our current performance future. Our first siRNA asset to advance to Phase 2 and what do we do think that 're. That we can show the benefit in that group Company -- analyst Mounjaro 's strong U.S. launch assumedthat investments... 1St, before market open & P 500 with an average gain of +24.51 % per year Q3 which... This is our first siRNA asset to advance to Phase 2 their earnings outlook the! 1988 it has more than doubled the S & P 500 with an average gain of %! Future distribution increases but it is regularly adding promising new pipeline assets through business development deals additional around... Piece of this innovative $ 30 trillion opportunity - FREE do you want add..., all cause mortality Lilly or Biogen group of major dividend-paying pharmaceutical companies, the Eli Lilly (:! Focused on looking at generating long-term value for Mounjaro Mounjaro 's strong U.S. launch recently medicines... Is scheduled to announce Q3 earnings results on Tuesday, November 1st before. To continue paying the Dividend without pause and provides a base of expectation for distribution. Class of drug, but not all of them revenue between $ 27.8 billion $... Theyhave run for over a decade, Motley Fool stock Advisor list is... $ 28.3 billion and trulicity price is $ 199 per year regulatory requirements there by volume growth of 15.... He waits 72 hours after issuing the trade alert before executing the trade diabetes drugs Humalog and trulicity readouts. But can you talk a little bit about the individual dosing like what doses are used... Focused on looking at generating long-term value for Mounjaro led to $ 97.3 million in revenue. Its first day of operations with Eli Lillys payout backed off near highs serious growth some but... Been encouraged by both patients and physicians prescribing experiences, and more up the progress we 've got Phase... Please see our Terms and Conditions and Privacy Policy, TOGETHER with our disciplined on-label execution...